Report error Found 120 of ic50 data for complexid = 270
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 62.8nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 202nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 418nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 418nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 422nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 795nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.62E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.28E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.96E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.35E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.68E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.97E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 5.39E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.17E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.25E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.25E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.30E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.73E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 9.32E+3nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.10E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.67E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.69E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.73E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.75E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.76E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.96E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 1.99E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.06E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.33E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 2.41E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 3.04E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 3.14E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 3.29E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 3.36E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 3.44E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 3.54E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.07E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.33E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.57E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.70E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.73E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 4.82E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 5.00E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 5.00E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 5.08E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 5.49E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 5.75E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 5.83E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Human)
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 5.84E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
